Zynex Reaches 400 Salesperson Milestone Ahead of Schedule
Zynex, Inc. (NASDAQ: ZYXI), a leader in non-invasive medical devices, announced it has reached 400 sales representatives in the U.S., surpassing its target of 400 ahead of the September 30 deadline. The company aims to increase this number to 500 by the end of 2020 and over 600 by the end of 2021. CEO Thomas Sandgaard highlighted the opportunity presented by increased unemployment due to COVID-19, improving rep productivity, and positioning the NexWave device as a non-opioid treatment option. Zynex focuses on advocating for pain management solutions to reduce addiction risks.
- Reached 400 sales reps ahead of target.
- Anticipates growth to 500 reps by year-end 2020 and 600 by 2021.
- Improved sales rep productivity through enhanced onboarding and training.
- Positioning NexWave as a first-line treatment for pain management.
- None.
ENGLEWOOD, Colo., Sept. 10, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced reaching four hundred sales reps in the U.S.
Thomas Sandgaard, CEO of Zynex said: "We continue to aggressively hire sales reps and we've reached four hundred sales reps ahead of our original target of September 30. We continue to see qualified candidates in the market due to increased unemployment rates related to COVID-19. Our continued investment in new sales rep onboarding and training has increased our rep productivity which we expect to drive order growth in the second half of 2020 and beyond. We expect to have approximately 500 sales reps in the U.S. by the end of 2020 and over 600 by the end of 2021."
Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain. We continue to add additional sales reps in territories throughout the US that we have not covered previously.
We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."
About Zynex
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including our Annual Report on Form 10-K for the year ended December 31, 2019 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
Zynex, Inc.
(800) 495-6670
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content:http://www.prnewswire.com/news-releases/zynex-reaches-400-salesperson-milestone-ahead-of-schedule-301126716.html
SOURCE Zynex
FAQ
What is Zynex's recent announcement regarding sales representatives?
How many sales reps does Zynex plan to have by the end of 2020?
What is the goal for Zynex's sales reps by the end of 2021?
How does Zynex's NexWave device relate to pain management?
How has COVID-19 impacted Zynex's hiring strategy?
